Surprise win for Corcept's glucocorticoid therapy

Not enrolling some patients into the phase 3 Rosella study of relacorilant has apparently helped Corcept Therapeutics score a win in this trial, but even so the result isn't as emphatic as phase 2 data had promised. Rosella was carried out in platinum-resistant ovarian cancer, but excluded patients with primary platinum-refractory disease and four or more prior therapy lines, after a subgroup analysis of phase 2 data suggested that this would increase the chances of Rosella hitting co-primary PFS and OS endpoints. On Monday Rosella was toplined positive for PFS, and interim OS was also said to be numerically positive, with Corcept saying it would take relacorilant to regulators. Still, Rosella combined relacorilant with Abraxane, and compared this only against Abraxane alone; possible treatment options in platinum-resistant ovarian cancer also include doxorubicin, gemcitabine and topotecan. Another unusual fact is that relacorilant isn't an advanced cancer therapy but rather an oral glucocorticoid receptor antagonist that Corcept is also studying in Cushing’s syndrome. Corcept stock more than doubled on the Rosella data on Monday, giving the company a $10bn valuation, though at least part of this will have been due to short positions being covered.

Relacorilant + Abraxane, vs Abraxane, in platinum-resistant ovarian cancer

Source: Corcept presentations.